BR112018015164A2 - single stranded oligonucleotide - Google Patents

single stranded oligonucleotide

Info

Publication number
BR112018015164A2
BR112018015164A2 BR112018015164A BR112018015164A BR112018015164A2 BR 112018015164 A2 BR112018015164 A2 BR 112018015164A2 BR 112018015164 A BR112018015164 A BR 112018015164A BR 112018015164 A BR112018015164 A BR 112018015164A BR 112018015164 A2 BR112018015164 A2 BR 112018015164A2
Authority
BR
Brazil
Prior art keywords
nucleotide sequence
oligonucleotide
single stranded
hybridization
stranded oligonucleotide
Prior art date
Application number
BR112018015164A
Other languages
Portuguese (pt)
Inventor
Nakajima Hiroyuki
KANAKI Tatsuro
Iriyama Yusuke
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59398721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018015164(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of BR112018015164A2 publication Critical patent/BR112018015164A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a um oligonucleotídeo de fita simples que é capaz de controlar um gene alvo com alta eficiência e pode ser facilmente produzido. o oligonucleotídeo de fita simples é representado pela fórmula x-l-y onde x e y hibridizam através de uma primeira porção de sequência de nucleotídeos e uma segunda porção de sequência de nucleotídeos. x é composto por 7 a 100 nucleotídeos, contém pelo menos um nucleotídeo modificado, e tem uma primeira sequência de nucleotídeos que é capaz de hibridização com um segundo oligonucleotídeo e contém pelo menos quatro nucleotídeos contíguos reconhecidos por rnase h. y é composto por 4 a 100 nucleotídeos, e tem uma segunda sequência de nucleotídeos que é capaz de hibridização com um segundo oligonucleotídeo e contém pelo menos um ribonucleotídeo. pelo menos uma de sequência de nucleotídeos x e sequência de nucleotídeos y tem uma sequência antissentido capaz de hibridização com um rna alvo. l é um grupo derivado de um terceiro oligonucleotídeo que é degradado sob condições fisiológicas.The present invention relates to a single stranded oligonucleotide that is capable of controlling a target gene with high efficiency and can be readily produced. The single stranded oligonucleotide is represented by the formula x-1-y where x and y hybridize through a first nucleotide sequence portion and a second nucleotide sequence portion. x is composed of 7 to 100 nucleotides, contains at least one modified nucleotide, and has a first nucleotide sequence that is capable of hybridization with a second oligonucleotide and contains at least four contiguous nucleotides recognized by rase h. y is comprised of 4 to 100 nucleotides, and has a second nucleotide sequence that is capable of hybridization to a second oligonucleotide and contains at least one ribonucleotide. at least one of nucleotide sequence x and nucleotide sequence y has an antisense sequence capable of hybridization to a target rna. 1 is a group derived from a third oligonucleotide that is degraded under physiological conditions.

BR112018015164A 2016-01-26 2017-01-26 single stranded oligonucleotide BR112018015164A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016012804 2016-01-26
JP2016158833 2016-08-12
PCT/JP2017/002831 WO2017131124A1 (en) 2016-01-26 2017-01-26 Single-stranded oligonucleotide

Publications (1)

Publication Number Publication Date
BR112018015164A2 true BR112018015164A2 (en) 2018-12-26

Family

ID=59398721

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015164A BR112018015164A2 (en) 2016-01-26 2017-01-26 single stranded oligonucleotide

Country Status (10)

Country Link
US (2) US11530409B2 (en)
EP (1) EP3409779A4 (en)
JP (3) JP6988481B2 (en)
CN (2) CN108884462B (en)
AU (1) AU2017211461B2 (en)
BR (1) BR112018015164A2 (en)
CA (1) CA3023222A1 (en)
MX (2) MX2018009090A (en)
TW (2) TWI803455B (en)
WO (1) WO2017131124A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131124A1 (en) * 2016-01-26 2017-08-03 日産化学工業株式会社 Single-stranded oligonucleotide
TWI830693B (en) 2017-02-06 2024-02-01 日商日產化學工業股份有限公司 single stranded oligonucleotide
CA3070809A1 (en) 2017-07-26 2019-01-31 Nissan Chemical Corporation Single-stranded oligonucleotide
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
EP3981431A4 (en) 2019-03-14 2023-06-28 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
EP4098747A1 (en) 2020-01-31 2022-12-07 Sanwa Kagaku Kenkyusho Co., Ltd. Antisense oligonucleotide of atn1
WO2021177418A1 (en) 2020-03-04 2021-09-10 日産化学株式会社 Antisense oligonucleotide of calm2
JPWO2022211129A1 (en) * 2021-04-01 2022-10-06
EP4353266A1 (en) 2021-05-31 2024-04-17 Rena Therapeutics Inc. Ligand-bound nucleic acid complex

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08154687A (en) 1994-12-12 1996-06-18 Yamanouchi Pharmaceut Co Ltd Anti-sense oligonucleotide and antiviral agent
JPH09110894A (en) 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk Hybric dna/rna oligonucleotide and antiviral agent
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JPH11137260A (en) 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk Anti-influenza viral cyclic dumbbell type rna-dna chimera compound and anti-influenza viral agent
AU6055299A (en) 1998-09-21 2000-04-10 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
EP1141413A2 (en) * 1998-12-31 2001-10-10 Gene Logic Inc. Assay device comprising mixed probes
CN1370178A (en) * 1999-06-25 2002-09-18 洞察战略及销售有限公司 Polynucletoides and polypeptides encoded through distantly homogous to heparanase
EP1627061B1 (en) * 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
ATE508188T1 (en) * 2002-02-01 2011-05-15 Life Technologies Corp OLIGONUCLEOTIDE COMPOSITIONS WITH IMPROVED EFFECTIVENESS
JP4383176B2 (en) 2002-02-13 2009-12-16 武 今西 Nucleoside analogues and oligonucleotide derivatives containing the nucleotide analogues thereof
EP1448590A4 (en) 2002-02-20 2004-12-15 Sirna Therapeutics Inc Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
GB0205455D0 (en) * 2002-03-07 2002-04-24 Molecular Sensing Plc Nucleic acid probes, their synthesis and use
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
WO2004015075A2 (en) 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004044134A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20080188429A1 (en) 2002-12-27 2008-08-07 Iyer Radhakrishnan P Synthetic siRNA compounds and methods for the downregulation of gene expression
ATE439438T1 (en) 2003-05-23 2009-08-15 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SINA (SHORT INTERFERING NUCLEIC ACID)
ES2569927T3 (en) 2003-06-11 2016-05-13 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
DK1661905T3 (en) 2003-08-28 2012-07-23 Takeshi Imanishi Novel N-O cross-linking synthetic nucleic acids
ZA200706083B (en) * 2005-02-01 2008-09-25 Alcon Inc RNAI-mediated inhibition of ocular targets
CN102124107A (en) * 2006-07-17 2011-07-13 瑟纳治疗公司 RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
CN101301478A (en) * 2007-05-10 2008-11-12 贝勒医学院 G-tetrad oligonucleotide using hypoxia inducible factor 1-alpha (HIFI alpha) as target
WO2010011895A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
WO2011052436A1 (en) 2009-10-29 2011-05-05 国立大学法人大阪大学 Bridged artificial nucleoside and nucleotide
BR112012022570A2 (en) * 2010-03-08 2015-10-06 Monsato Technology Llc polynucleotide molecules for gene regulation in plants.
EP2558578B1 (en) 2010-04-13 2015-10-28 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
JP4965745B2 (en) * 2010-08-03 2012-07-04 株式会社ボナック Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2013040429A1 (en) * 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
EP2791335B1 (en) 2011-12-16 2018-11-14 National University Corporation Tokyo Medical and Dental University Chimeric double-stranded nucleic acid
JP5876890B2 (en) * 2012-01-07 2016-03-02 株式会社ボナック Single-stranded nucleic acid molecule having amino acid skeleton
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
CN103114131B (en) * 2012-11-30 2018-10-02 珠海市坤元农业科技有限公司 A kind of primer middle part sequence interferes round pcr
CN103333890B (en) * 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 RNA interference preparation used for treating viral hepatitis B
AU2014259755B2 (en) 2013-05-01 2018-08-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
AU2014272526A1 (en) 2013-05-30 2015-12-10 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
CN104419702A (en) * 2013-09-04 2015-03-18 北京中康万达医药科技有限公司 Method for screening siRNA on basis of bioinformatics
KR102357337B1 (en) 2013-12-27 2022-01-28 가부시키가이샤 보낙 Artificial match-type mirna for controlling gene expression and use therefor
WO2015105083A1 (en) 2014-01-07 2015-07-16 塩野義製薬株式会社 Double-stranded oligonucleotide containing antisense oligonucleotide and sugar derivative
WO2015113922A1 (en) * 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
JPWO2016152352A1 (en) 2015-03-20 2018-01-11 国立大学法人名古屋大学 Melanoma-specific biomarkers and uses thereof
WO2017131124A1 (en) * 2016-01-26 2017-08-03 日産化学工業株式会社 Single-stranded oligonucleotide
EP3493834A1 (en) * 2016-08-07 2019-06-12 Novartis AG Mrna-mediated immunization methods
TWI830693B (en) 2017-02-06 2024-02-01 日商日產化學工業股份有限公司 single stranded oligonucleotide
CA3070809A1 (en) * 2017-07-26 2019-01-31 Nissan Chemical Corporation Single-stranded oligonucleotide
AU2019237599A1 (en) * 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
ES2927412T3 (en) * 2018-11-08 2022-11-04 Siemens Healthcare Gmbh Direct sequencing of RNA nanopores with the aid of a hairpin polynucleotide
KR20210129645A (en) * 2019-01-22 2021-10-28 코로 바이오, 인크. RNA-editing oligonucleotides and uses thereof
WO2021177418A1 (en) * 2020-03-04 2021-09-10 日産化学株式会社 Antisense oligonucleotide of calm2

Also Published As

Publication number Publication date
JP2022050389A (en) 2022-03-30
AU2017211461A1 (en) 2018-09-13
EP3409779A4 (en) 2019-07-03
CA3023222A1 (en) 2017-08-03
JPWO2017131124A1 (en) 2018-11-15
JP2024056807A (en) 2024-04-23
CN108884462A (en) 2018-11-23
CN108884462B (en) 2022-11-25
TW202334427A (en) 2023-09-01
US20190119683A1 (en) 2019-04-25
CN116064544A (en) 2023-05-05
MX2023002818A (en) 2023-03-17
MX2018009090A (en) 2019-03-28
EP3409779A1 (en) 2018-12-05
TWI803455B (en) 2023-06-01
JP7435583B2 (en) 2024-02-21
WO2017131124A1 (en) 2017-08-03
JP6988481B2 (en) 2022-01-05
TW201738376A (en) 2017-11-01
US11530409B2 (en) 2022-12-20
AU2017211461B2 (en) 2023-01-12
US20230203498A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
BR112018015164A2 (en) single stranded oligonucleotide
Borah Primer designing for PCR
ES2610461T3 (en) Unique nucleotide detection method
BR112016019267A2 (en) dna profile methods and compositions
EP4328322A3 (en) Probe library construction
JP2017002079A5 (en)
WO2017037304A3 (en) An assembly system for a eukaryotic cell
MX2019002075A (en) Compositions comprising reversibly modified oligonucleotides and uses thereof.
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
CY1124197T1 (en) ANTINOHMATIKA POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHODS OF TREATMENT OF DYSTROPHIES
BR112017016423A2 (en) Method to Improve Ability to Resist against Plant Intrusive DNA Viruses
JP2016537990A5 (en)
MY157531A (en) Td probe and its uses
PE20190843A1 (en) RNA ADDRESSING TO GENERIC DNA
AR100946A1 (en) COMPOSITIONS AND METHODS TO REGULATE GENE EXPRESSION THROUGH RNA INTERFERENCE
JP2012223202A5 (en)
RU2015150098A (en) METHOD OF DNA AMPLIFICATION BASED ON INTRODUCTION TO THE CHAIN
MX361191B (en) Detection of target nucleic acid sequence by pto cleavage and extension-dependent non-hybridization assay.
MX2019009305A (en) Single-stranded oligonucleotide.
JP2014030431A5 (en)
DE60309817D1 (en) Dual-purpose primers and probes for improved hybridization assays by destroying secondary structures
Xu et al. Real-time quantitative nicking endonuclease-mediated isothermal amplification with small molecular beacons
JP2018068317A5 (en)
Sakhabutdinova et al. Inhibition of nonspecific polymerase activity using poly (aspartic) acid as a model anionic polyelectrolyte
AR088216A1 (en) AGENTS FOR THE CONTROL OF THE AVISPA DE LAS AGALLAS

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023003774-0 PROTOCOLO 870230017145 EM 28/02/2023 16:34.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]